sagopilone (BAY86-5302) / Bayer - LARVOL DELTA

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer (Lung Cancer) - P2, N=128; Sponsor: Bayer; NCT00160069; “Eight patients across all arms had a confirmed partial response; the primary endpoint was not achieved. The most frequently reported adverse event (AE) was peripheral sensory neuropathy (75%). Most hematologic AEs were grade 1 or 2.”

P2 data • Non Small Cell Lung Cancer